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Hae-Ryong Yun, MD; Jung Tak Park, MD, PhD; Tae-Hyun Yoo, MD, PhD; Su Ah Sung, MD, PhD; Kyu-Beck Lee, MD, PhD; Kook-Hwan Oh, MD,
PhD; Soo Wan Kim, MD, PhD; Joongyub Lee, MD, PhD; Shin-Wook Kang, MD, PhD; Kyu Hun Choi, MD, PhD; Curie Ahn, MD, PhD;
Seung Hyeok Han, MD, PhD; on behalf of the KNOW-CKD (Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease)
Investigators††
Background-—High-density lipoprotein cholesterol (HDL-C) levels are generally decreased in patients with chronic kidney disease
(CKD). However, studies on the relationship between HDL-C and CKD progression are scarce.
Methods and Results-—We studied the association between serum HDL-C levels and the risk of CKD progression in 2168
participants of the KNOW-CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease). The primary outcome
was the composite of a 50% decline in estimated glomerular ﬁltration rate from baseline or end-stage renal disease. The secondary
outcome was the onset of end-stage renal disease. During a median follow-up of 3.1 (interquartile range, 1.6–4.5) years, the
primary outcome occurred in 335 patients (15.5%). In a fully adjusted Cox model, the lowest category with HDL-C of <30 mg/dL
(hazard ratio, 2.21; 95% CI, 1.30–3.77) and the highest category with HDL-C of ≥60 mg/dL (hazard ratio, 2.05; 95% CI, 1.35–3.10)
were associated with a signiﬁcantly higher risk of the composite renal outcome, compared with the reference category with HDL-C
of 50 to 59 mg/dL. This association remained unaltered in a time-varying Cox analysis. In addition, a fully adjusted cubic spline
model with HDL-C being treated as a continuous variable yielded similar results. Furthermore, consistent ﬁndings were obtained in
a secondary outcome analysis for the development of end-stage renal disease.
Conclusions-—A U-shaped association was observed between serum HDL-C levels and adverse renal outcomes in this large cohort
of patients with CKD. Our ﬁndings suggest that both low and high serum HDL-C levels may be detrimental to patients with
nondialysis CKD. ( J Am Heart Assoc. 2019;8:e011162. DOI: 10.1161/JAHA.118.011162.)
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S erum high-density lipoprotein (HDL) has traditionally beenconsidered to be protective against cardiovascular
disease in the general population. HDL exerts an anti-
atherogenic effect through reverse cholesterol transport, a
multiorgan process that removes excess cholesterol from
lipid-laden macrophages and peripheral tissue.1 In addition,
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normal HDL also confers protection against atherosclerosis
through different mechanisms, including anti-inﬂammatory,
antioxidative, and antithrombotic effects. The exact mecha-
nisms of these effects are unknown, but previous studies have
suggested a possible role of minor HDL components, such as
apolipoprotein E, apolipoprotein A-IV, and apolipoprotein J.2–4
Not surprisingly, several epidemiologic studies have demon-
strated a clear inverse association between serum HDL
cholesterol (HDL-C) and the risk of cardiovascular disease.5–7
However, recent studies questioned the relevance of HDL-C
as a surrogate marker for HDL-related cardiovascular risk.
Randomized clinical trials that aimed at increasing HDL-C
levels showed no clinical beneﬁt in reducing cardiovascular
risk.8–10 In addition, mendelian randomization analyses failed
to show a causal association between genetically elevated
HDL-C levels and risk for myocardial infarction.11 Further-
more, there is accumulating evidence showing that the
composition of HDL determines its functional properties,
rather than the levels of circulating HDL-C.12 Taken together,
these ﬁndings raise a concern about the previous notion that
high serum HDL-C levels confer protection against adverse
outcomes.
Chronic kidney disease (CKD) has become a serious health
concern worldwide, given the high burden of cardiovascular
events and death in patients with this condition.13,14
Dyslipidemia is common in patients with CKD and is
characterized by lower levels of HDL-C and higher levels of
triglyceride and oxidized low-density lipoprotein cholesterol.15
A growing body of evidence suggests that low HDL-C levels are
associated with an increased risk of renal dysfunction in the
general population.16–20 However, the relationship between
serum HDL-C levels and disease progression in patients with
CKD who are not yet undergoing dialysis has not been fully
examined, and previous studies on this issue have shown
contradictory results.21–24 In addition, these studies were all
limited by analyzing only baseline HDL-C (ie, changes in HDL-C
levels over time were not taken into account). Therefore, the
prognostic value of HDL-C with respect to disease progression
in patients with nondialysis CKD remains unclear. Interestingly,
in keeping with the aforementioned uncertainty about the
protective role of high HDL-C levels, a recent large-scale
epidemiologic study demonstrated a U-shaped relationship
between serum HDL-C levels and incident CKD or CKD
progression in the general population, in which the risk of
adverse renal outcome was increased in the lowest and highest
deciles of HDL-C.19 In addition, it was found that HDL
composition and function is signiﬁcantly altered in patients
with CKD, which leads not only to the loss of its protective
properties but also to its transformation into toxic particles.25
These ﬁndings led us to hypothesize that both low and high
serum HDL-C levels have a negative impact on renal function in
patients with nondialysis CKD. Therefore, this study aimed to
clarify the complex association between serum HDL-C levels
and the risk of CKD progression in a large prospective cohort of
patients with CKD.
Materials and Methods
Study Design and Participants
The KNOW-CKD (Korean Cohort Study for Outcome in
Patients With Chronic Kidney Disease) is a prospective
nationwide cohort study investigating various clinical courses
and risk factors for the progression of CKD in Korean patients.
Patients, aged between 20 and 75 years, with CKD stages
from 1 to 5 before dialysis, who voluntarily provided informed
consent, were enrolled from 9 tertiary-care general hospitals
throughout Korea between June 2011 and February 2016. The
study rationale, design, methods, and protocol summary are
provided in detail elsewhere (NCT01630486 at http://
www.clinicaltrials.gov).26 Among 2238 patients in the
KNOW-CKD cohort, 70 with missing data of HDL-C levels
were excluded. Finally, 2168 patients were included in the
present analysis.
The data that support the ﬁndings of this study are
available from the KNOW-CKD investigators on reasonable
request. The request can initially be sent to the corresponding
author, then will be distributed to the investigators. The
relevant data, analytical methods, and study materials will be
open to researchers after a comprehensive discussion.
Clinical Perspective
What Is New?
• Compared with a reference category with high-density
lipoprotein cholesterol (HDL-C) of 50 to 59 mg/dL, both low
(<30 mg/dL) and high (≥60 mg/dL) HDL-C levels were
associated with an increased risk of disease progression in
patients with chronic kidney disease who were not yet
undergoing dialysis.
• The time-varying Cox analysis and cubic spline model
further supported these ﬁndings, showing that the associ-
ation between HDL-C and adverse renal outcome follows a
nonlinear U-shaped relationship.
What Are the Clinical Implications?
• Both low and high HDL-C levels could be harmful with
respect to chronic kidney disease progression.
• Our ﬁndings support the result of previous studies showing
that HDL-C becomes dysfunctional and even transforms into
toxic particles in patients with chronic kidney disease.
• Future research should focus on the role of the composition
and function of HDL in the progression of chronic kidney
disease rather than its levels alone.
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Data Collection and Measurements
Demographic details, including age, sex, smoking status,
alcohol intake, physical activity, medical history, and comor-
bid diseases, were obtained from the KNOW-CKD database.
Smoking status was classiﬁed as never, former, or current.
Alcohol intake was categorized as none, moderate (<20 g/d),
or high (≥20 g/d). The weekly frequency of moderate- or
vigorous-intensity physical activity was also investigated.
Anthropometric data, including height and weight, were
collected at enrollment. Body mass index (BMI) was calcu-
lated as initial body weight divided by height squared (kg/m2).
Blood pressure was measured in the sitting position after
subjects had been in a relaxed state for at least 5 minutes, by
using an electronic sphygmomanometer. After overnight
fasting, blood samples were collected and sent to the central
laboratory of KNOW-CKD (Lab Genomics, Seongnam, Korea)
for measurements of creatinine. Other biochemical analyses,
including lipid proﬁles, were done at the local laboratory of
each participating center. Most laboratory parameters were
measured every 6 months in the ﬁrst year and annually
thereafter, including complete blood cell count, fasting
glucose, blood urea nitrogen, creatinine, albumin, calcium,
and phosphorus. C-reactive protein, iron proﬁles (including
total iron-binding capacity and serum ferritin), and lipid
proﬁles (including triglyceride, HDL-C, and low-density lipopro-
tein cholesterol) were measured repeatedly after 1 year and
biennially thereafter. We used a creatinine method that
requires calibration traceable to isotope dilution mass spec-
trometry, and estimated glomerular ﬁltration rate (eGFR) was
calculated using the CKD Epidemiologic Collaboration equa-
tion.27 Along with blood samples, urine samples were also
immediately sent to the central laboratory for proteinuria
measurement. Urine albumin/creatinine ratio was calculated
as the urine albumin concentration divided by the urine
creatinine concentration (mg/g).
Exposure and Outcome Ascertainment
The exposures of interest were baseline and time-varying
serum HDL-C levels. Given a possible nonlinear relationship
with event rates, serum HDL-C levels were treated as a
categorical variable and divided into 5 categories with 10-mg/
dL increments: <30, 30 to <40, 40 to <50, 50 to <60
(reference), and ≥60 mg/dL. The reference category for each
analysis was selected as the fourth group because these
groups were the modal categories with the lowest event rates
and allowed for the most powerful analyses. We also treated
HDL-C level as a continuous variable and modeled a nonlinear
effect by using a restricted cubic spine function.
The primary outcome was a composite of a 50% decline in
eGFR from the baseline value or the onset of end-stage renal
disease (ESRD) during the follow-up period. ESRD was deﬁned
as the initiation of renal replacement therapy, including
dialysis or renal transplantation. The secondary outcome was
the development of ESRD. Patients were followed up until
December 31, 2016, and were censored at the date of the last
study visit, death, or the studied events.
Statistical Analyses
Cox proportional hazard regression models were separately
performed to study the associations of serum HDL-C levels
with subsequent renal outcomes using 2 approaches: (1) ﬁxed
models with baseline values were examined to ascertain the
association of long-term exposure with CKD progression, and
(2) time-varying models were assessed to account for
changes in exposure over time and to ascertain their short-
term associations.28 In time-varying analyses, all laboratory
data were incorporated as time-dependent variables. For each
analysis, unadjusted and 2 additional models were con-
structed on the basis of the level of multivariate adjustment:
(1) model 1: unadjusted; (2) model 2: demographic and
clinical characteristics of age, sex, study center (Seoul
National University Hospital, Seoul National University Bun-
dang Hospital, Yonsei University Severance Hospital, Kangbuk
Samsung Medical Center, Seoul St Mary’s Hospital, Gil
Hospital, Eulji General Hospital, Chonnam National University
Hospital, or Pusan Paik Hospital), comorbidities (diabetes
mellitus, hypertension, coronary artery disease, congestive
heart failure, peripheral arterial occlusive disease, cerebrovas-
cular disease, dementia, chronic obstructive pulmonary
disease, connective tissue disease, peptic ulcer disease, and
liver disease), smoking status (former or current versus
never), alcohol intake (none versus 1–19 or ≥20 g/d),
physical activity (<3 versus ≥3 times/week), and use of
lipid-modifying drugs (statin, ezetimibe, ﬁbrates, and others);
and (3) model 3 (fully adjusted): model 2 plus anthropometric
and laboratory parameters, including BMI, systolic blood
pressure, serum low-density lipoprotein cholesterol, triglyc-
eride, white blood cell count, fasting glucose, albumin,
calcium, phosphorus, total iron-binding capacity, ferritin, C-
reactive protein, eGFR, and random urine albumin/creatinine
ratio. In addition, we explored the continuous, potentially
nonlinear relationship between HDL-C levels and the studied
outcomes by using fully adjusted restricted cubic spline
models with 4 knots. For sensitivity analysis, we also repeated
analyses using HDL-C categorized into quintiles, where the
range of quintiles was <36, 36 to <43, 43 to <50.3, 50.3 to
<60, and ≥60 mg/dL for baseline HDL-C and <37, 37 to <44,
44 to <51, 51 to <61, and ≥61 mg/dL for time-varying HDL-C
values.
To test the robustness of our ﬁndings, we then performed
subgroup analyses using baseline HDL-C values, which
include age (<60 versus ≥60 years), sex, diabetic CKD, statin
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use, BMI (<25 versus ≥25 kg/m2), systolic blood pressure
(<130 versus ≥130 mm Hg), serum albumin concentration
(<4.0 versus ≥4.0 g/dL), C-reactive protein levels (<0.6
versus ≥0.6 mg/dL), and eGFR (<15 versus ≥15 mL/min
per 1.73 m2) at baseline. All exposure-event associations
were expressed as hazard ratios (HRs) and 95% CIs. Data from
descriptive analyses were summarized using meansSD,
medians (interquartile ranges), or proportions, as appropriate,
and were compared using Student t test, ANOVA, Kruskal-
Wallis test, and v2 test. Statistical signiﬁcance was deﬁned as
P<0.05. All statistical analyses were performed using Stata,
version 14.2 (Stata Corporation, College Station, TX).
Ethics Statement
We performed the study in accordance with the Declaration of
Helsinki, and the study protocol was approved by the
institutional review board of each participating clinical center
(in 2011), as follows: Seoul National University Hospital
(1104-089-359), Seoul National University Bundang Hospital
(B-1106/129-008), Yonsei University Severance Hospital (4-
2011-0163), Kangbuk Samsung Medical Center (2011-01-
076), Seoul St Mary’s Hospital (KC11OIMI0441), Gil Hospital
(GIRBA2553), Eulji General Hospital (201105-01), Chonnam
National University Hospital (CNUH-2011-092), and Pusan
Paik Hospital (11-091).
Results
Baseline Characteristics of the Study Population
The demographic, clinical, and laboratory characteristics of the
patients, according to HDL-C categories, are presented in
Table 1. Among the 2168 participants, 1335 (61.6%) weremen.
Their meanSD age was 53.712.2 years, and their
meanSD HDL-C level was 49.215.4 mg/dL. Low
(<40 mg/dL) and high (≥60 mg/dL) HDL-C levels were
observed in 614 patients (28.3%) and 460 patients (21.2%),
respectively. Patients with a higher HDL-C were younger; were
more likely to be women and never smokers; and had fewer
comorbid conditions, such as diabetes mellitus, hypertension,
coronary artery disease, and cerebrovascular disease. In
addition, these patients had a lower blood pressure and were
less obese and less inﬂamed than those with a lower HDL-C.
Kidney function was more preserved and the amount of urinary
protein excretion was lower in patients with a higher HDL-C.
HDL-C and Risk of CKD Progression
During a median follow-up of 3.1 (interquartile range, 1.6–4.5)
years, the primary outcome occurred in 335 patients (15.5%).
The composite adverse renal outcome occurred most
commonly in patients with diabetic nephropathy than in those
with other causes of CKD (Table 2). As expected, more patients
with a lower eGFR at baseline reached a ≥50% decline in eGFR,
or ESRD (Table 2). We then evaluated renal outcomes among
HDL-C categories. The primary outcome occurred in 32 (34.4%),
97 (18.6%), 89 (14.0%), 56 (12.2%), and 61 (13.3%) of patients
with baseline HDL-C levels of <30, 30 to 39, 40 to 49, 50 to 59,
and ≥60 mg/dL, respectively (P<0.001) (Table 3). The unad-
justed HRs in the categories of HDL-C levels of <30 and
≥60 mg/dL were 3.42 (95% CI, 2.21–5.28) and 1.10 (95% CI,
0.77–1.59), respectively, compared with the category of HDL-C
level of 50 to <60 mg/dL (model 1). This association was not
changed after adjustment for demographic factors, comorbidi-
ties, and medications (model 2). However, in a fully adjusted
Coxmodel in which BMI, systolic blood pressure, and laboratory
parameters were additionally included, the risk of the compos-
ite renal outcome was signiﬁcantly higher in both the lowest
(HR, 2.21; 95%CI, 1.30–3.77) and the highest (HR, 2.05; 95%CI,
1.35–3.10) categories (Table 3, Figure 1). The time-varying
analysis consistently showed an increased risk of the compos-
ite renal outcome in the groups with HDL-C levels of <30 mg/
dL (HR, 2.06; 95% CI, 1.18–3.61) and ≥60 mg/dL (HR, 1.62;
95% CI, 1.05–2.52), compared with the reference category
(Table 3, Figure 1). Restricted cubic spline models with HDL-C
being treated as a continuous variable yielded a similar result
(Figure 2). The association of HDL-C with the composite renal
outcome followed a U-shaped trend, indicating an increased
risk of CKD progression with low and high HDL-C levels.
HDL-C and Risk of ESRD
The ﬁndings from analyses of primary outcome remained
unaltered in separate analyses of secondary outcome
(development of ESRD). ESRD developed in 30 (32.3%), 81
(15.6%), 71 (11.2%), 41 (8.9%), and 51 (11.1%) of patients
with HDL-C levels of <30, 30 to 39, 40 to 49, 50 to 59, and
≥60 mg/dL, respectively (P<0.001) (Table 4). Both groups
with low (<30 mg/dL; HR, 3.42; 95% CI, 1.87–6.27) and
high (≥60 mg/dL; HR, 3.24; 95% CI, 2.00–5.27) baseline
levels of HDL-C had a higher risk of ESRD development
than the reference group with a baseline HDL-C level of 50
to 59 mg/dL (Table 4, Figure 3). In addition, we observed a
similar association between HDL-C levels and the risk of
ESRD in the time-varying Cox analysis (Table 4, Figure 3). A
U-shaped association between HDL-C level and ESRD
development was also found in restricted cubic spline
models (Figure 4).
Subgroup Analyses
The results of subgroup analyses are shown in Figure 5. A
signiﬁcant association of low baseline HDL-C (<30 mg/dL)
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Table 1. Baseline Characteristics of Patients According to Baseline HDL-C Levels Categorized Into 5 Groups
Characteristics
Total
(n=2168)
Baseline Serum HDL-C Concentrations, mg/dL
P Value
for Trend
<30
(n=93, 4.3%)
30–<40
(n=521, 24.0%)
40–<50
(n=635, 29.3%)
50–<60
(n=459, 21.2%)
≥60
(n=460, 21.2%)
Age, y 53.712.2 57.210.8 55.711.6 54.112.1 52.612.5 51.412.6 <0.001
Sex (men), % 61.6 80.6 77.4 67.2 55.1 38.5 <0.001
Cause of CKD, %
Glomerulonephritis 36.2 16.1 30.9 36.7 40.1 41.5 <0.001
Diabetic
nephropathy
23.2 58.1 30.9 24.9 15.0 13.3 <0.001
Hypertension 18.5 18.3 22.6 20.5 17.2 12.2 <0.001
Polycystic
kidney disease
16.1 5.4 1.0 11.0 22.7 25.9 <0.001
Others 6.0 2.2 5.6 6.9 5.0 7.2 0.237
Comorbidities, %
DM 33.9 68.8 41.1 37.0 24.6 23.5 <0.001
Hypertension 96.1 97.8 99.0 97.3 95.0 92.0 <0.001
Coronary
artery disease
1.7 4.3 3.1 1.9 0.7 0.2 <0.001
CHF 1.5 2.2 1.9 1.9 1.3 0.7 0.068
PAOD 3.6 4.3 4.6 3.0 4.1 2.4 0.141
Cerebrovascular
disease
6.0 6.5 7.3 6.0 7.0 3.5 0.043
Dementia 0.0 0.0 0.0 0.2 0.0 0.0 0.556
COPD 0.6 1.1 0.4 1.1 0.2 0.2 0.244
Connective
tissue disease
6.2 3.2 7.7 6.3 5.9 5.4 0.411
Peptic ulcer
disease
1.8 1.1 1.3 2.0 1.3 2.4 0.314
Liver disease 2.6 2.2 3.3 3.1 1.5 2.4 0.269
Smoking status, %
Never 53.6 40.9 38.2 52.5 59.0 69.5 <0.001
Former 30.6 36.6 41.8 30.4 26.1 21.4 <0.001
Current 15.8 22.6 20.0 17.0 14.8 9.2 <0.001
Alcohol intake, %
None 79.5 83.2 79.4 77.4 81.3 77.3 0.167
Moderate (1–19 g/d) 8.7 7.5 9.8 9.8 8.7 7.3 0.681
High (≥20 g/d) 11.8 9.3 10.9 12.8 9.9 15.4 0.035
Physical activity, %
<3 Times/wk 61.8 63.0 64.1 62.4 59.3 60.0 0.179
≥3 Times/wk 38.2 37.0 35.9 37.6 40.7 40.0 0.179
Body mass
index, kg/m²
24.63.4 25.42.8 25.43.2 25.03.3 24.43.5 23.23.4 <0.001
Blood pressure, mm Hg
SBP 128.616.6 131.119.2 129.417.0 129.016.0 127.416.0 127.816.8 0.017
DBP 76.811.2 74.813.1 76.611.1 76.810.7 77.210.9 76.911.8 0.197
MAP 111.313.7 112.316.0 111.814.0 111.613.2 110.713.1 110.814.3 0.118
Continued
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with CKD progression was evident particularly in men; in
those with a lower BMI (<25 kg/m2) and systolic blood
pressure (<130 mm Hg); and in those with higher albumin
(≥4.0 g/dL) and C-reactive protein (≥0.6 mg/dL) levels
(Figure 5A). On the other hand, there was a consistent
trend of the impact of baseline high HDL-C with respect to
CKD progression in most of the stratiﬁed groups (Fig-
ure 5B).
Sensitivity Analyses
To test the robustness and consistency of our ﬁndings, we
conducted a sensitivity analysis in which participants were
recategorized according to quintiles of HDL-C. The risk of the
composite renal outcome was signiﬁcantly higher in both the
ﬁrst (HR, 1.56; 95% CI, 1.01–2.39) and ﬁfth (HR, 2.11; 95% CI,
1.38–3.24) quintiles compared with the fourth quintile of
Table 1. Continued
Characteristics
Total
(n=2168)
Baseline Serum HDL-C Concentrations, mg/dL
P Value
for Trend
<30
(n=93, 4.3%)
30–<40
(n=521, 24.0%)
40–<50
(n=635, 29.3%)
50–<60
(n=459, 21.2%)
≥60
(n=460, 21.2%)
Antihypertensive agents, %
ACEi 11.2 9.7 10.4 12.5 10.0 11.7 0.692
ARB 80.1 77.4 85.4 80.6 79.3 74.6 <0.001
Diuretics 31.8 51.6 39.8 34.9 25.3 20.9 <0.001
b Blockers 25.1 37.9 32.1 29.2 20.5 13.5 <0.001
CCB 40.9 57.0 48.1 41.8 36.8 32.2 <0.001
Lipid-modifying agents, %
Statin 51.9 52.7 54.4 51.9 52.1 48.7 0.113
Ezetimibe 6.5 8.6 7.1 8.4 4.1 5.0 0.019
Fibrates 2.8 7.5 3.1 2.8 2.8 1.3 0.008
Other lipid-modifying
drugs
2.4 3.2 3.1 2.5 2.4 1.5 0.111
Baseline eGFR,
mL/min per 1.73 m²
50.630.4 31.221.8 41.324.7 50.028.9 54.930.8 61.334.1 <0.001
Lipid parameters, mg/dL
TC 174.139.1 142.633.3 162.038.3 172.837.3 179.137.0 191.237.1 <0.001
LDL-C 96.931.7 77.326.4 90.930.9 99.931.8 100.630.9 99.531.9 <0.001
HDL-C 49.215.4 26.04.5 35.02.7 44.32.8 54.12.9 72.012.9 <0.001
Triglyceride 157.798.6 213.0119.6 199.1105.1 162.893.1 140.9100.6 109.857.8 <0.001
Other laboratory parameters
WBC, 9103/lL 6.61.9 7.32.2 7.11.9 6.71.9 6.41.8 6.11.9 <0.001
Fasting glucose,
mg/dL
111.140.0 117.647.1 112.840.6 113.639.9 108.138.1 104.333.1 <0.001
Albumin, g/dL 4.20.4 4.00.5 4.10.4 4.20.4 4.20.4 4.20.4 0.013
Calcium, mg/dL 9.10.5 8.80.7 9.00.5 9.20.5 9.20.5 9.20.6 <0.001
Phosphorus, mg/dL 3.70.7 3.80.8 3.70.7 3.70.7 3.60.6 3.70.7 0.923
TIBC, mg/dL 297.852.2 276.960.5 288.649.6 300.252.3 300.850.8 306.352.2 <0.001
Ferritin, ng/mL 99.8 (53.9–176.3) 147.3 (71.6–258.4) 114.6 (65.1–189.4) 108.8 (59.1–186.2) 96.2 (48.9–169.2) 74.7 (37.8–129.0) <0.001
CRP, mg/dL 0.6 (0.2–1.7) 0.9 (0.5–2.5) 0.9 (0.3–2.2) 0.7 (0.3–1.8) 0.5 (0.2–1.5) 0.3 (0.1–1.0) 0.001
UACR, mg/g 354.1 (77.9–1086.0) 529.1 (119.3–1332.1) 424.5 (106.1–1264.1) 340.9 (83.4–1095.0) 315.1 (70.1–948.3) 308.4 (50.4–1039.6) 0.046
Values for categorical variables are given as number (percentage); values for continuous variables are given as meanSD or median (interquartile range). eGFR was calculated using the
CKD–Epidemiology Collaboration equation. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CHF, congestive
heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated
glomerular ﬁltration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MAP, mean arterial pressure; PAOD, peripheral arterial occlusive disease;
SBP, systolic blood pressure; TC, total cholesterol; TIBC, total iron-binding capacity; UACR, urine albumin/creatinine ratio; WBC, white blood cell.
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baseline HDL-C (Table S1, Figure S1). The time-varying Cox
analysis showed that the ﬁfth quintile of HDL-C (HR, 1.61;
95% CI, 1.02–2.52) had a higher risk of the composite renal
outcome than the fourth quintile, whereas the risk of the
composite renal outcome was not signiﬁcantly different in the
ﬁrst quintile of HDL-C (HR, 1.32; 95% CI, 0.85–2.06). Similar
results were obtained in the secondary outcome analyses for
the development of ESRD (Table S2, Figure S2). The risk of
ESRD was higher in both the ﬁrst (HR, 2.05; 95% CI, 1.24–
3.41) and ﬁfth (HR, 3.52; 95% CI, 2.13–5.82) quintiles of HDL-
C than the fourth quintile of baseline HDL-C. This association
remained unaltered in a time-varying Cox analysis.
Discussion
In this large, prospective, cohort study, we showed that,
compared with a reference category with HDL-C of 50 to
59 mg/dL, both low (<30 mg/dL) and high (≥60 mg/dL) HDL-
C levels were associated with an increased risk of disease
progression in patients with CKD who were not yet undergoing
dialysis. The time-varying Cox analysis and cubic spline model
further supported these ﬁndings, showing that the association
between HDL-C and adverse renal outcome follows a nonlinear
U-shaped relationship. Our ﬁndings suggest that both low and
high HDL-C levels may contribute to the progression of CKD in
patients not yet undergoing dialysis.
Low HDL-C is a traditional risk factor for future cardiovas-
cular events.7 In line with this, several epidemiologic studies
have suggested an association between low HDL-C and poor
renal function in the general population.16–20 Low HDL-C
predicted an increased risk of renal dysfunction in 12 728
participants from the ARIC (Atherosclerosis Risk in Commu-
nities) cohort study with baseline serum creatinine of
<2.0 mg/dL in men and <1.8 mg/dL in women.16 More
recently, Bowe et al also showed a signiﬁcant relationship
between low levels of HDL-C and an increased risk of incident
CKD and its progression in a cohort of almost 2 million male
veterans over a median follow-up of 9 years.19 Notably, there
was a U-shaped relationship between HDL-C level and the
future development of CKD in this study, and high HDL-C level
was also associated with adverse renal outcomes. However, it
is unclear whether these ﬁndings can be extrapolated to the
whole CKD population because this study included only white
elderly veteran men who had normal kidney function (eGFR,
>60 mL/min per 1.73 m2) at study initiation.
To date, studies on the relationship between HDL-C levels
and adverse renal outcome in nondialysis patients with CKD
are scarce and have shown conﬂicting results.21–24 Baragetti
et al showed that low HDL-C levels were associated with
earlier entry to a dialysis program or doubling of the plasma
creatinine levels in 176 patients with CKD.23 In addition, the
MDRD (Modiﬁcation of Diet in Renal Disease) Study revealed
that lower HDL-C independently predicted a faster decline in
kidney function in 840 patients with diverse renal diseases.22
In contrast, a recent publication by the CRIC (Chronic Renal
Insufﬁciency Cohort) study investigators showed that HDL-C
Table 2. Clinical Outcomes According to Cause of CKD or eGFR Categories
Outcomes
Patients Renal Outcomes ≥50% Decline in eGFR ESRD
No. % No. % No. % No. %
Overall outcome 2168 100.0 335 15.5 170 7.8 274 12.6
Cause of CKD
Glomerulonephritis 784 36.2 87 11.1 46 5.9 67 8.6
Diabetic nephropathy 503 23.2 147 29.2 62 12.3 128 25.5
Hypertension 400 18.5 42 10.5 24 6.0 37 9.3
Polycystic kidney disease 350 16.1 47 13.4 30 8.6 33 9.4
Others 131 6.0 12 9.2 8 6.1 9 6.9
eGFR categories at T0, mL/min per 1.73 m2
≥90 260 12.0 3 1.2 2 0.8 1 0.4
<90–≥60 401 18.5 6 1.5 6 1.5 3 0.8
<60–≥45 392 18.1 19 4.9 16 4.1 8 2.0
<45–≥30 473 21.8 50 10.6 44 9.3 32 6.8
<30–≥15 502 23.2 162 32.3 85 16.9 137 27.3
<15 140 6.5 95 67.9 17 12.1 93 66.3
CKD indicates chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease; T0, at baseline.
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was not independently associated with the composite end
point of ESRD or a 50% reduction in eGFR in 3939 adults with
CKD.24 However, HR was determined per 1-SD increase of
HDL-C; thus, the insigniﬁcant results of the study might be
attributable to an inability to distinguish the nonlinear
associations among HDL-C categories. Moreover, all the
previous studies were limited by analyzing only the baseline
HDL-C levels. Our study sought to overcome the limitations of
previous studies by analyzing both the baseline HDL-C
measurements and the HDL-C changes during the follow-up
Table 3. Association of HDL-C Levels With Composite Renal Outcome in the Baseline and Time-Varying Cox Analysis
HDL-C Level
Patient Event Model 1 Model 2 Model 3
No. % No. % HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Baseline
HDL-C, mg/dL
2168 100.0 335 15.5 . . . . . . . . . . . . . . . . . .
<30 93 4.3 32 34.4 3.42 (2.21–5.28) <0.001 2.46 (1.56–3.88) <0.001 2.21 (1.30–3.77) 0.003
30–<40 521 24.0 97 18.6 1.64 (1.18–2.27) 0.003 1.45 (1.03–2.04) 0.032 1.28 (0.85–1.91) 0.233
40–<50 635 29.3 89 14.0 1.21 (0.87–1.69) 0.261 1.10 (0.78–1.55) 0.585 1.26 (0.86–1.84) 0.242
50–<60 459 21.2 56 12.2 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
≥60 460 21.2 61 13.3 1.10 (0.77–1.59) 0.597 1.22 (0.84–1.76) 0.298 2.05 (1.35–3.10) 0.001
Time-varying HDL-C, mg/dL
<30     4.57 (2.95–7.09) <0.001 3.50 (2.22–5.56) <0.001 2.06 (1.18–3.61) 0.011
30–<40     1.92 (1.35–2.72) <0.001 1.58 (1.09–2.29) 0.016 1.15 (0.75–1.77) 0.533
40–<50     1.61 (1.14–2.28) 0.007 1.40 (0.98–2.02) 0.068 1.51 (1.01–2.26) 0.045
50–<60     1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
≥60     1.30 (0.89–1.90) 0.170 1.28 (0.86–1.90) 0.217 1.62 (1.05–2.52) 0.031
Model 1: unadjusted; model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral arterial
occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), smoking status (former or
current vs never), alcohol intake (none vs 1–19 or ≥20 g/d), physical activity (<3 vs ≥3 times/week), and lipid-modifying drugs (statin, ezetimibe, ﬁbrates, and others); model 3: adjusted
for model 2 plus body mass index, systolic blood pressure, and laboratory ﬁndings (white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-binding capacity,
ferritin, C-reactive protein, low-density lipoprotein cholesterol, triglyceride, estimated glomerular ﬁltration rate, and urine albumin/creatinine ratio). HDL-C indicates high-density
lipoprotein cholesterol; HR, hazard ratio.
Figure 1. Associations of baseline (A) and time-varying (B) serum high-density lipoprotein cholesterol (HDL-C) levels with composite renal
outcomes (hazard ratios and 95% CI error bars). Adjustments in model 1: unadjusted; model 2: age, sex, study center, comorbidities, smoking
status, alcohol intake, physical activity, and use of lipid-modifying drugs; and model 3: model 2 plus body mass index, systolic blood pressure,
serum low-density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-binding
capacity, ferritin, C-reactive protein level, estimated glomerular ﬁltration rate, and random urine albumin/creatinine ratio.
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period in a large cohort of patients with CKD. In this regard,
our ﬁndings provide robust evidence that both low and high
HDL-C levels were associated with an increased risk of CKD
progression in patients with nondialysis CKD.
CKD has an impact on serum HDL-C levels that is
determined by the rate of HDL-mediated reverse cholesterol
uptake from peripheral tissues and unloading of its
cholesterol cargo in the liver.29 HDL-mediated reverse
cholesterol uptake is signiﬁcantly impaired in chronic inﬂam-
matory and oxidative stress conditions, such as CKD.30
Reduced production and increased catabolism of apolipopro-
tein A1, downregulation of lecithin-cholesterol acyltrans-
ferase, and upregulation of acyl–coenzyme A cholesterol
acyltransferase-1 can contribute to the defective HDL-
Table 4. Association of HDL-C Levels With Development of ESRD in the Baseline and Time-Varying Cox Analysis
HDL-C Level
Patient Event Model 1 Model 2 Model 3
No. % No. % HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Baseline HDL-C, mg/dL 2168 100.0 274 12.6 . . . . . . . . . . . . . . . . . .
<30 93 4.3 30 32.3 4.34 (2.71–6.96) <0.001 2.98 (1.82–4.89) <0.001 3.42 (1.87–6.27) <0.001
30–<40 521 24.0 81 15.6 1.87 (1.28–2.72) 0.001 1.62 (1.10–2.38) 0.015 1.69 (1.06–2.71) 0.029
40–<50 635 29.3 71 11.2 1.32 (0.90–1.94) 0.157 1.21 (0.81–1.79) 0.353 1.54 (0.98–2.43) 0.062
50–<60 459 21.2 41 8.9 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
≥60 460 21.2 51 11.1 1.26 (0.83–1.89) 0.278 1.47 (0.96–2.24) 0.074 3.24 (2.00–5.27) <0.001
Time-varying HDL-C, mg/dL
<30     5.89 (3.61–9.61) <0.001 4.42 (2.61–7.51) <0.001 3.28 (1.71–6.30) 0.001
30–<40     2.43 (1.61–3.66) <0.001 1.97 (1.26–3.06) 0.003 1.78 (1.05–3.01) 0.033
40–<50     1.88 (1.24–2.83) 0.003 1.64 (1.06–2.54) 0.027 2.06 (1.24–3.43) 0.005
50–<60     1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
≥60     1.57 (1.01–2.45) 0.044 1.64 (1.03–2.62) 0.039 2.64 (1.55–4.48) <0.001
Model 1: unadjusted; model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral arterial
occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), smoking status (former or
current vs never), alcohol intake (none vs 1–19 or ≥20 g/d), physical activity (<3 vs ≥3 times/week), and lipid-modifying drugs (statin, ezetimibe, ﬁbrates, and others); model 3: adjusted
for model 2 plus body mass index, systolic blood pressure, and laboratory ﬁndings (white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-binding capacity,
ferritin, C-reactive protein, low-density lipoprotein cholesterol, triglyceride, estimated glomerular ﬁltration rate, and urine albumin/creatinine ratio). ESRD indicates end-stage renal disease;
HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio.
Figure 2. Adjusted hazard ratios of composite renal outcomes associated with baseline (A) and time-varying (B) serum high-density
lipoprotein cholesterol (HDL-C) concentrations in a Cox model using restricted cubic spines. All models were adjusted for age, sex, study center,
comorbidities, smoking status, alcohol intake, physical activity, use of lipid-modifying drugs, body mass index, systolic blood pressure, serum
low-density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-binding
capacity, ferritin, C-reactive protein level, estimated glomerular ﬁltration rate, and random urine albumin/creatinine ratio.
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mediated cholesterol uptake in CKD.31 In addition, modiﬁca-
tion of apolipoprotein A1 by reactive oxygen species (oxida-
tion), elevated urea level (carbamylation), and systemic
inﬂammation (myeloperoxidase modiﬁcation) impairs the
ability of HDL to bind to the machinery mediating cholesterol
efﬂux via ATP-binding cassette transporter A1 and G1.32
Furthermore, the unloading of HDL-C cargo is also impaired in
CKD. The aforementioned modiﬁcations may limit the binding
of HDL to scavenger receptor-B1, leading to defective
disposal of HDL-C cargo in the liver.33 Advanced oxidation
protein products, which are carried by oxidized plasma protein
and accumulate in renal disease,34 also bind to scavenger
receptor-B1 with high afﬁnity and further prevent cholesterol
inﬂux.25 Taken together, reverse cholesterol transport prop-
erties are defective in the patients with CKD because both
HDL-mediated reverse cholesterol uptake and unloading
capacity of its cholesterol cargo are impaired. However, their
effects on HDL-C levels are opposite: impaired cholesterol
uptake from peripheral tissues leads to HDL-C deﬁciency,
whereas compromised HDL-C unloading capacity increases
Figure 3. Associations of baseline (A) and time-varying (B) serum high-density lipoprotein cholesterol (HDL-C) levels with end-stage renal
disease (ESRD; hazard ratios and 95% CI error bars). Adjustments in model 1: unadjusted; model 2: age, sex, study center, comorbidities,
smoking status, alcohol intake, physical activity, and use of lipid-modifying drugs; and model 3: model 2 plus body mass index, systolic blood
pressure, serum low-density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total
iron-binding capacity, ferritin, C-reactive protein level, estimated glomerular ﬁltration rate, and random urine albumin/creatinine ratio.
Figure 4. Adjusted hazard ratios of end-stage renal disease (ESRD) associated with baseline (A) and time-varying (B) serum high-density
lipoprotein cholesterol (HDL-C) concentrations in a Cox model using restricted cubic spines. All models were adjusted for age, sex, study
center, comorbidities, smoking status, alcohol intake, physical activity, use of lipid-modifying drugs, body mass index, systolic blood pressure,
serum low-density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-binding
capacity, ferritin, C-reactive protein level, estimated glomerular ﬁltration rate, and random urine albumin/creatinine ratio.
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serum HDL-C levels. In this regard, high HDL-C in CKD might,
in part, indicate defective reverse cholesterol transport, rather
than improved HDL function.
Although HDL-C levels are affected by CKD itself, our study
showed that both low and high HDL-C levels could be harmful
with respect to CKD progression, suggesting a bidirectional
association between 2 factors. Nevertheless, it is still unclear
whether low HDL-C is causally linked to the progression of
CKD. In addition to the altered HDL metabolism in CKD, low
HDL-C levels might be attributed to poor overall metabolic
health, which can contribute to the decline in kidney
function.35 In fact, some genetic studies and randomized
clinical trials suggested that low HDL-C might simply be a
marker reﬂecting residual risk rather than an independent
driver of adverse outcomes.8–10,36 For instance, Coassin et al
revealed that the genetic variants having the strongest
associations with HDL-C levels were not related to kidney
function.36 In addition, pharmacologic agents that increase
serum HDL-C, such as niacin and cholesterol ester transfer
protein inhibitors, had no effect on cardiovascular events and
renal function in randomized clinical trials.8–10 However, we
clearly showed an independent association of low HDL-C with
CKD progression, even after a rigorous adjustment for
multiple confounding factors. Our ﬁndings are supported by
experimental studies demonstrating that HDL-C deﬁciency or
dysfunction induced renal vascular atherosclerosis and
glomerular and tubulointerstitial injury.37–39 Furthermore, a
recent mendelian randomization study suggested a small, but
robust, causal association between HDL-C concentration and
eGFR in the general population.32 These ﬁndings together
raise the possibility of a causal association between low HDL-
C and renal dysfunction.
The association between HDL-C and the risk of adverse
renal outcome follows a U-shaped curve, suggesting that high
HDL-C could also be harmful with respect to CKD progres-
sion. Several studies can explain the possible mechanisms
responsible for this phenomenon. An experimental study by
Huang et al showed that moderate to high concentrations of
HDL in healthy subjects paradoxically impaired endothelial
progenitor cells and angiogenesis in the absence of oxidized
low-density lipoprotein, suggesting the biphasic effects of
HDL.40 In addition, accumulating evidence shows that
inﬂammation and oxidative stress can impair reverse choles-
terol transport and reduce the anti-inﬂammatory and
Figure 5. Adjusted hazard ratios (and 95% CI error bars) of composite renal outcomes for the low
(<30 mg/dL; A) and high (≥60 mg/dL; B) high-density lipoprotein cholesterol (HDL-C) categories vs the
reference group (30–<60 mg/dL) of baseline HDL-C levels in various subgroups. All models were adjusted
for age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, use of lipid-
modifying drugs, body mass index (BMI), systolic blood pressure (SBP), serum low-density lipoprotein
cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron-
binding capacity, ferritin, C-reactive protein (CRP) level, estimated glomerular ﬁltration rate (eGFR), and
urine albumin/creatinine ratio. CKD indicates chronic kidney disease.
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antioxidant properties of HDL.41 Interestingly, CKD involves a
high level of inﬂammation accompanied by a high burden of
oxidative stress,42 and the antioxidant and anti-inﬂammatory
activity of HDL is diminished in patients with CKD.43–45 A
reduced activity of HDL-associated antioxidant enzymes,
such as paraoxonase-1, glutathione peroxidase, and lecithin-
cholesterol acyltransferase, can contribute to these ﬁndings
in CKD.31 Furthermore, HDL can transform into the opposite
pro-oxidant and proinﬂammatory directions in CKD.44,46 This
was demonstrated by Speer et al, who showed that HDL in
patients with CKD reduced endothelial NO availability via toll-
like receptor-2, leading to impaired endothelial repair,
increased proinﬂammatory activation, and increased blood
pressure.47 This transformation can be facilitated by the
oxidative modiﬁcation of apolipoprotein A1 and other com-
ponents of HDL and the accumulation of proinﬂammatory
proteins, such as serum amyloid-A, which promote cytokine
production and increase the endothelial production of
reactive oxygen species.31,48 In accordance with these
ﬁndings, several observational studies showed paradoxical
associations between elevated HDL-C levels and cardiovas-
cular events or mortality in certain conditions with chronic
inﬂammation, particularly in patients undergoing hemodialy-
sis.29,49–51 Therefore, it can be presumed that high levels of
toxic HDL particles in CKD might contribute to adverse
outcomes, including deterioration of kidney function.
Several shortcomings of this study should be considered.
First, given the observational nature of the study, it is possible
that potential confounding factors were not entirely con-
trolled. However, this study included a large number of
participants and analyzed the data by using various multivari-
able Cox models after a rigorous adjustment for measured
covariates. Second, most of the patients in our study had
relatively preserved kidney function; thus, the association
between HDL-C and CKD progression needs to be veriﬁed in
patients with advanced stages of CKD. However, the results of
subgroup analysis by baseline eGFR were consistent with the
main ﬁndings, and a signiﬁcant association was also seen in
patients with advanced CKD. Third, HDL-C levels were
measured at the local laboratory of each participating center,
not the central laboratory. This could raise a concern about
imprecision and bias among various methods for measuring
HLD-C.52 However, all laboratories in our study used the same
direct enzymatic assay for the measurement. In addition, to
mitigate bias associated with the center effect, this was
adjusted in the multivariable model and the results were
consistent. Fourth, we did not conduct a qualitative assess-
ment of HDL-C composition and function, or HDL-C sub-
classes. As aforementioned, some researchers have
suggested the importance of alterations in the composition
and function of HDL-C, rather than the quantity of HDL-C.
Nevertheless, we clearly showed the biphasic association of
HDL-C with adverse renal outcome by using various statistical
models and suggested that quantitative assessment can also
explain the complex role of HDL-C in patients with CKD.
Finally, as the event rates for cardiovascular disease or
mortality were low because of the relatively short duration of
follow-up, we did not investigate the relationship between
HDL-C and cardiovascular events or mortality. Future reports
from the KNOW-CKD will focus on these issues.
In conclusion, both low and high HDL-C levels were
associated with an increased risk of disease progression in
patients with nondialysis CKD, showing a nonlinear U-shaped
relationship. Our ﬁndings support the results of previous
studies showing that HDL-C becomes dysfunctional and even
transforms into toxic particles in patients with CKD. Future
research should focus on the role of the composition and
function of HDL in the progression of CKD, rather than its
levels alone.
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Table S1. Association of quintiles of high-density cholesterol levels with composite renal outcome in the baseline and time-varying Cox 
analyses. 
  
Patient   Event   Model 1   Model 2  Model 3  
 
No %  No %  HR (95% CI) P  HR (95% CI) P  HR (95% CI) P 
Baseline HDL-C (mg/dL) 2,168 100.0  335 15.5          
     Quintile 1 369 17.0  92 24.9  2.23 (1.58-3.14) <0.001  1.81 (1.26-2.59) 0.001  1.56 (1.01-2.39) 0.045 
     Quintile 2 449 20.7  69 15.4  1.34 (0.93-1.92) 0.113   1.24 (0.85-1.79) 0.259  1.31 (0.86-1.98) 0.211 
     Quintile 3 483 22.3  62 12.8  1.06 (0.73-1.54) 0.743   0.97 (0.67-1.42) 0.889  1.24 (0.81-1.90) 0.316 
     Quintile 4 407 18.8  51 12.5  1.00 (Reference)    1.00 (Reference)   1.00 (Reference)  
     Quintile 5 460 21.2  61 13.3  1.08 (0.75-1.57) 0.680   1.19 (0.82-1.74) 0.365  2.11 (1.38-3.24) 0.001 
Time-varying HDL-C (mg/dL)              
     Quintile 1 - -  - -  2.50 (1.76-3.55) <0.001  2.04 (1.40-2.98) <0.001 1.32 (0.85-2.06) 0.217 
     Quintile 2 - -  - -  1.57 (1.08-2.28) 0.019   1.35 (0.91-2.01) 0.138  1.15 (0.74-1.80) 0.538 
     Quintile 3 - -  - -  1.41 (0.96-2.08) 0.081   1.32 (0.88-1.97) 0.184  1.54 (0.98-2.41) 0.061 
     Quintile 4 - -  - -  1.00 (Reference)    1.00 (Reference)   1.00 (Reference)  
     Quintile 5 - -  - -  1.27 (0.86-1.87) 0.225   1.28 (0.86-1.93) 0.226  1.61 (1.02-2.52) 0.039 
HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval 
Model 1: unadjusted; Model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, 
peripheral arterial occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, liver 
disease), smoking status (former or current vs never), alcohol intake (none vs 1–19 g/d or ≥20 g/d), physical activity (<3 times/wk vs ≥3 times/wk), and lipid modifying 
drugs (statin, ezetimibe, fibrates, and others); Model 3: adjusted for model 2 + body mass index, systolic blood pressure, and laboratory findings (white blood cell, fasting 
glucose, albumin, calcium, phosphorus, total iron binding capacity, ferritin, C-reactive protein, low-density lipoprotein cholesterol, triglyceride, estimated glomerular 
filtration rate, and urine albumin-to-creatinine ratio) 
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Table S2. Association of quintiles of high-density cholesterol levels with development of ESRD in the baseline and time-varying Cox 
analyses. 
  
Patient   Event   Model 1   Model 2  Model 3  
 
No %  No %  HR (95% CI) P  HR (95% CI) P  HR (95% CI) P 
Baseline HDL-C (mg/dL) 2,168 100.0  274 12.6          
     Quintile 1 369 17.0  78 21.1  2.58 (1.75-3.82) <0.001  2.00 (1.32-3.02) 0.001  2.05 (1.24-3.41) 0.005 
     Quintile 2 449 20.7  59 13.1  1.60 (1.06-2.41) 0.026   1.48 (0.97-2.26) 0.067  1.78 (1.09-2.92) 0.021 
     Quintile 3 483 22.3  49 10.1  1.16 (0.76-1.77) 0.503   1.07 (0.69-1.66) 0.775  1.66 (0.99-2.76) 0.054 
     Quintile 4 407 18.8  37 9.1  1.00 (Reference)    1.00 (Reference)   1.00 (Reference)  
     Quintile 5 460 21.2  51 11.1  1.24 (0.81-1.90) 0.314   1.46 (0.95-2.26) 0.088  3.52 (2.13-5.82) <0.001 
Time-varying HDL-C (mg/dL)              
     Quintile 1 - -  - -  2.86 (1.92-4.28) <0.001  2.19 (1.41-3.39) <0.001 1.74 (1.02-2.96) 0.041 
     Quintile 2 - -  - -  1.87 (1.22-2.86) 0.004   1.60 (1.01-2.51) 0.043  1.67 (0.99-2.83) 0.055 
     Quintile 3 - -  - -  1.48 (0.94-2.32) 0.089   1.33 (0.82-2.14) 0.244  1.92 (1.10-3.33) 0.021 
     Quintile 4 - -  - -  1.00 (Reference)    1.00 (Reference)   1.00 (Reference)  
     Quintile 5 - -  - -  1.42 (0.91-2.21) 0.121   1.44 (0.90-2.31) 0.126  2.28 (1.39-4.06) 0.001 
ESRD, end-stage renal disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; CI, confidence interval 
Model 1: unadjusted; Model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral 
arterial occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), 
smoking status (former or current vs never), alcohol intake (none vs 1–19 g/d or ≥20 g/d), physical activity (<3 times/wk vs ≥3 times/wk), and lipid modifying drugs 
(statin, ezetimibe, fibrates, and others); Model 3: adjusted for model 2 + body mass index, systolic blood pressure, and laboratory findings (white blood cell, fasting glucose, 
albumin, calcium, phosphorus, total iron binding capacity, ferritin, C-reactive protein
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Figure S1. Association of quintiles of high-density cholesterol levels with composite renal 
outcome in the (A) baseline and (B) time-varying Cox analyses (hazard ratios and 95% 
confidence interval error bars). 
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Figure S2. Association of quintiles of high-density cholesterol levels with end-stage renal 
disease in the (A) baseline and (B) time-varying Cox analyses (hazard ratios and 95% 
confidence interval error bars). 
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